Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 294 Companies   490 Products   490 Products   198 Mechanisms of Action   25 Trials   7787 News 


«12...1314151617181920212223...156157»
  • ||||||||||  Proleukin (aldesleukin) / Novartis, Prometheus, Iovance Biotherap
    Enrollment open, Trial initiation date, Trial primary completion date:  ANEMIL: Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (clinicaltrials.gov) -  May 25, 2017   
    P1/2,  N=10, Recruiting, 
    Enrolling by invitation --> Completed | N=50 --> 88 | Initiation date: Nov 2015 --> Mar 2015 | Trial primary completion date: Nov 2016 --> Feb 2017 Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017 | Trial primary completion date: Jul 2019 --> Dec 2019
  • ||||||||||  Rebif (human IFN-β-1a) / EMD Serono
    Trial completion, Enrollment change, HEOR:  RLO: Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif (clinicaltrials.gov) -  May 24, 2017   
    P=N/A,  N=296, Completed, 
    Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | N=600 --> 296
  • ||||||||||  cyclophosphamide / Generic mfg.
    Biomarker, Trial completion, IO biomarker:  OMS: Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome (clinicaltrials.gov) -  May 23, 2017   
    P=N/A,  N=400, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Plivensia (sirukumab) / J&J
    Trial initiation date, Trial primary completion date:  Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica (clinicaltrials.gov) -  May 23, 2017   
    P3,  N=150, Not yet recruiting, 
    Trial primary completion date: Dec 2018 --> Mar 2017 Initiation date: Jun 2017 --> Mar 2018 | Trial primary completion date: Jan 2020 --> Aug 2020
  • ||||||||||  Trial completion, Enrollment change:  GotNet Study, The Gothenburg Nurse-led Tight Control Study (clinicaltrials.gov) -  May 19, 2017   
    P=N/A,  N=70, Completed, 
    N=252 --> 24 | Recruiting --> Suspended | Trial primary completion date: Apr 2017 --> Sep 2017 Active, not recruiting --> Completed | N=120 --> 70
  • ||||||||||  Trial completion:  AbATE Follow-Up Study (clinicaltrials.gov) -  May 18, 2017   
    P=N/A,  N=44, Completed, 
    N=16 --> 0 | Trial primary completion date: Dec 2015 --> Aug 2016 Active, not recruiting --> Completed
  • ||||||||||  aspirin / Generic mfg.
    Trial completion, Trial primary completion date:  Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis (clinicaltrials.gov) -  May 18, 2017   
    P,  N=12, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2017 --> May 2017
  • ||||||||||  Enrollment open, Trial primary completion date:  SPIRALE: Study During Pregnancy of Expression of miRNAs in RA or SLE (clinicaltrials.gov) -  May 17, 2017   
    P=N/A,  N=40, Recruiting, 
    Recruiting --> Completed | Trial primary completion date: Sep 2017 --> May 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Jul 2019
  • ||||||||||  ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
    Trial completion, Trial primary completion date:  A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (clinicaltrials.gov) -  May 17, 2017   
    P3,  N=0, Completed, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Jul 2019 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2017
  • ||||||||||  Enrollment closed, Phase classification, Trial primary completion date:  Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) -  May 17, 2017   
    P=N/A,  N=178, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2017 Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A | Trial primary completion date: Sep 2018 --> Sep 2017
  • ||||||||||  Trial primary completion date, Adherence:  APRim: Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis (clinicaltrials.gov) -  May 16, 2017   
    P=N/A,  N=560, Recruiting, 
    Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A | Trial primary completion date: Sep 2018 --> Sep 2017 Trial primary completion date: Aug 2017 --> Dec 2017
  • ||||||||||  Enrollment change, Trial termination:  The Clinical Efficacy of DFPP in Patients With AAGN (clinicaltrials.gov) -  May 16, 2017   
    P=N/A,  N=14, Terminated, 
    Trial primary completion date: Mar 2017 --> Oct 2018 N=70 --> 14 | Recruiting --> Terminated; The recruitment of subject is very difficult.
  • ||||||||||  Trial completion:  HYKRAND: Studies on the Adaptive Responses to Hypoxia (clinicaltrials.gov) -  May 16, 2017   
    P=N/A,  N=30, Completed, 
    N=70 --> 14 | Recruiting --> Terminated; The recruitment of subject is very difficult. Recruiting --> Completed
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Enrollment closed, Phase classification, Trial primary completion date:  NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) -  May 15, 2017   
    P=N/A,  N=40, Active, not recruiting, 
    Recruiting --> Completed Enrolling by invitation --> Active, not recruiting | Phase classification: P4 --> PN/A | Trial primary completion date: May 2017 --> Jan 2018
  • ||||||||||  Orencia (abatacept) / BMS
    Trial completion, P4 data, Combination therapy:  Abatacept Post-marketing Clinical Study in Japan (clinicaltrials.gov) -  May 15, 2017   
    P4,  N=405, Completed, 
    Enrolling by invitation --> Active, not recruiting | Phase classification: P4 --> PN/A | Trial primary completion date: May 2017 --> Jan 2018 Active, not recruiting --> Completed